Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and-202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency

Imagem de Miniatura
Arquivos
art_COSTALONGA_Growth_hormone_pharmacogenetics_the_interactive_effect_of_a_2012.PDF (2.96 MB)
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
ANTONINI, S. R. R.
GUERRA-JUNIOR, G.
Citação
PHARMACOGENOMICS JOURNAL, v.12, n.5, p.439-445, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Insulin-like growth factor type 1 (IGF1) is a mediator of growth hormone (GH) action, and therefore, IGF1 is a candidate gene for recombinant human GH (rhGH) pharmacogenetics. Lower serum IGF1 levels were found in adults homozygous for 19 cytosine-adenosine (CA) repeats in the IGF1 promoter. The aim of this study was to evaluate the influence of (CA)n IGF1 polymorphism, alone or in combination with GH receptor (GHR)-exon 3 and -202 A/C insulin-like growth factor binding protein-3 (IGFBP3) polymorphisms, on the growth response to rhGH therapy in GH-deficient (GHD) patients. Eighty-four severe GHD patients were genotyped for (CA) n IGF1, -202 A/C IGFBP3 and GHR-exon 3 polymorphisms. Multiple linear regressions were performed to estimate the effect of each genotype, after adjustment for other influential factors. We assessed the influence of genotypes on the first year growth velocity (1st y GV) (n = 84) and adult height standard deviation score (SDS) adjusted for target-height SDS (AH-TH SDS) after rhGH therapy (n = 37). Homozygosity for the IGF1 19CA repeat allele was negatively correlated with 1st y GV (P = 0.03) and AH-TH SDS (P = 0.002) in multiple linear regression analysis. In conjunction with clinical factors, IGF1 and IGFBP3 genotypes explain 29% of the 1st y GV variability, whereas IGF1 and GHR polymorphisms explain 59% of final height-target-height SDS variability. We conclude that homozygosity for IGF1 (CA) 19 allele is associated with less favorable short-and long-term growth outcomes after rhGH treatment in patients with severe GHD. Furthermore, this polymorphism exhibits a non-additive interaction with -202 A/C IGFBP3 genotype on the 1st y GV and with GHR-exon 3 genotype on adult height. The Pharmacogenomics Journal (2012) 12, 439-445; doi:10.1038/tpj.2011.13; published online 5 April 2011
Palavras-chave
dwarfism, growth hormone/deficiency, growth hormone/therapeutic use, pharmacogenetics, insulin-like growth factor type 1, genetic variation
URI
https://observatorio.fm.usp.br/handle/OPI/499
Referências
  1. Arends N, 2002, J CLIN ENDOCR METAB, V87, P2720, DOI 10.1210/jc.87.6.2720
  2. Carel JC, 2002, BRIT MED J, V325, P70, DOI 10.1136/bmj.325.7355.70
  3. Clemmons DR, 2001, HORM RES, V55, P73, DOI 10.1159/000063480
  4. Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579
  5. Costalonga EF, 2009, J CLIN ENDOCR METAB, V94, P588, DOI 10.1210/jc.2008-1608
  6. de Ridder MAJ, 2007, J CLIN ENDOCR METAB, V92, P925, DOI 10.1210/jc.2006-1259
  7. Ester WA, 2008, BEST PRACT RES CL EN, V22, P415, DOI 10.1016/j.beem.2008.03.001
  8. Frayling TM, 2002, DIABETES, V51, P2313, DOI 10.2337/diabetes.51.7.2313
  9. FRISCH H, 1995, HORM RES, V43, P132, DOI 10.1159/000184258
  10. Geffner ME, 2007, HORM RES, V68, P51, DOI 10.1159/000110476
  11. Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990
  12. Harrela M, 1996, J CLIN INVEST, V98, P2612, DOI 10.1172/JCI119081
  13. Jernstrom H, 2001, CANCER EPIDEM BIOMAR, V10, P377
  14. Jorge AAL, 2006, J CLIN ENDOCR METAB, V91, P1076, DOI 10.1210/jc.2005-2005
  15. Jorge AAL, 2009, HORM RES, V71, P55, DOI 10.1159/000192438
  16. Kristrom B, 2002, HORM RES, V57, P66, DOI 10.1159/000058104
  17. Lettre G, 2007, HUM GENET, V122, P129, DOI 10.1007/s00439-007-0385-4
  18. Li HJ, 2005, J CLIN ENDOCR METAB, V90, P3659, DOI 10.1210/jc.2004-2079
  19. Li WT, 2000, HUM HERED, V50, P334, DOI 10.1159/000022939
  20. Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
  21. Ohlsson C, 2009, ENDOCR REV, V30, P494, DOI 10.1210/er.2009-0010
  22. Pantel J, 2000, J BIOL CHEM, V275, P18664, DOI 10.1074/jbc.M001615200
  23. Pyle S. I., 1959, RADIOGRAPHIC ATLAS S
  24. Ranke MB, 1999, J CLIN ENDOCR METAB, V84, P1174, DOI 10.1210/jc.84.4.1174
  25. Rietveld I, 2003, EUR J ENDOCRINOL, V148, P171, DOI 10.1530/eje.0.1480171
  26. Rocha MGM, 2008, J PEDIATR ENDOCR MET, V21, P673
  27. Rosen CJ, 1998, J CLIN ENDOCR METAB, V83, P2286, DOI 10.1210/jc.83.7.2286
  28. Silva EGP, 2003, HORM RES, V59, P229, DOI 10.1159/000070222
  29. Stochholm K, 2006, EUR J ENDOCRINOL, V155, P61, DOI 10.1530/eje.1.02191
  30. TANNER JM, 1966, ARCH DIS CHILD, V41, P613
  31. Vaessen N, 2001, DIABETES, V50, P637, DOI 10.2337/diabetes.50.3.637
  32. van der Kaay DCM, 2009, GROWTH HORM IGF RES, V19, P198, DOI 10.1016/j.ghir.2008.08.010
  33. Wassenaar MJE, 2009, J CLIN ENDOCR METAB, V94, P3721, DOI 10.1210/jc.2009-0425
  34. WEBER JL, 1989, AM J HUM GENET, V44, P388
  35. Wit JM, 1996, PEDIATR RES, V39, P295, DOI 10.1203/00006450-199602000-00018
  36. Wit JM, 2007, HORM RES, V68, P236
  37. Wit JM, 2007, HORM RES, V68, P244, DOI 10.1159/000101428

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - LIM/42